One thing that has not been mentioned with regard to Sanofi’s ouster of CEO Chris Viehbacher:
Although he has resigned his directorship and been removed as chief executive, there has been no mention of what happens to Viehbacher’s position as chairman of the board at Genzyme, Sanofi’s Cambridge, Mass.-based biotech outpost that was purchased for $20 billion in 2011. Viehbacher has already said he intends to live in Boston.
Hey, check out all the research scientist jobs. Post your resume today!
